2020
DOI: 10.1007/s12035-020-01916-3
|View full text |Cite
|
Sign up to set email alerts
|

Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 226 publications
0
6
0
Order By: Relevance
“…In this complex context, various roles have been attributed to the extracellular matrix (ECM) components over the past decades with regard to the determination of SCI evolution, including free growth factor availability, axonal regeneration, resident and incoming inflammatory cell activation, cell proliferation and migration and attempts at myelin repair. Altered ECM composition after injury is caused by the degradation of certain ECM components and the increased synthesis and activity of others [6]. Different metalloproteases (MMPs), for example, can be released by activated microglia/macrophages, a mechanism triggered by hyaluronan fragments, tenascins and sulfated proteoglycans liberated in the site of injury [7].…”
Section: Introductionmentioning
confidence: 99%
“…In this complex context, various roles have been attributed to the extracellular matrix (ECM) components over the past decades with regard to the determination of SCI evolution, including free growth factor availability, axonal regeneration, resident and incoming inflammatory cell activation, cell proliferation and migration and attempts at myelin repair. Altered ECM composition after injury is caused by the degradation of certain ECM components and the increased synthesis and activity of others [6]. Different metalloproteases (MMPs), for example, can be released by activated microglia/macrophages, a mechanism triggered by hyaluronan fragments, tenascins and sulfated proteoglycans liberated in the site of injury [7].…”
Section: Introductionmentioning
confidence: 99%
“…Previous studies on serum markers of SCI have mainly focused on inflammatory factors (such as IL-1β, TNF-a and IL-6), metalloproteinases (such as MMP-2, MMP-8 and MMP-9), chemokines (such as MCP-1 and CXCL12D), neuronal cell-specific proteins (such as neuron-specific enolase, NSE, etc. ), astrocyte-specific proteins (such as S-100 and GFAP), and oligodendrocyte-specific proteins (such as myelin basic protein (MBP)) [ [8] , [9] , [10] ]. Although findings suggest that structural proteins and inflammatory markers may be useful in assessing SCI severity and predicting neurological outcomes, the current level of evidence is generally low.…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, with the progress of molecular biology and genomics techniques, many studies have found that the levels of some structural proteins and inflammatory factors in cerebrospinal fluid and serum can reflect the degree of SCI [ [5] , [6] , [7] ]. In acute SCI models, Tau, S-100β, and NSE protein levels were found to be significantly increased [ 5 , [8] , [9] , [10] ]. The preliminary conclusion that serum NSE, serum albumin, and S-100β levels were correlated with the degree of spinal cord injury remains to be confirmed with a large sample size [ [11] , [12] , [13] , [14] ].…”
Section: Introductionmentioning
confidence: 99%
“…In SCI is a severe neurological disease with a high disability rate (20). To date, emerging effort has been made to identify critical regulators, which are involved in the pathogenesis of SCI, and the pharmacological therapies targeting these regulators have been developed for clinical trials to prevent neurological dysfunction (21,22). Recently, there is emerging evidence that a larger number of miRNAs are aberrantly expressed following SCI and might play a key role in the development of SCI (23).…”
Section: Discussionmentioning
confidence: 99%